Anadys second-quarter net reduction decreases to $3.0 million Anadys Pharmaceuticals, Inc. , a biopharmaceutical firm focused on improving patient treatment by developing novel medicines for the treatment of hepatitis C, today reported its financial outcomes and system highlights for the next quarter ended June 30, 2010 choline bitartrate http://dmae.review/ . In the second quarter we continued to progress the advancement of ANA598, and we enhanced the Company’s financial position through a $12.5M equity offering, said Steve Worland, Ph.D., CEO and President of Anadys. Financial Results By June 30, 2010, the business’s cash, money equivalents and securities available-for-sale totaled $22.1 million in comparison to $20.5 million as of December 31, 2009.4 million from our registered direct offering completed during June 2010 partially offset by the year-to-day cash utilization to invest in our operations, including expenditures associated with our Phase II combination study of ANA598.